Back to Market Feed

Product Information

DUPIXENT 300 MG/2 ML SYRINGE is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $1011.3804 per ML under NDC 00024591401. Its NADAC has been published 375 times since Jun 19, 2019.

DUPIXENT 300 MG/2 ML SYRINGE

Dupilumab
$1011.3804per ML

Strength

300 mg/2mL

NDC

00024591401

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Effective Date

8/19/2026

Active Ingredients

DUPILUMAB

Approval Type

Biologic (BLA)

FDA Application

BLA761055

On Market Since

3/28/2017

Pharmacological Classes

Antibodies
Monoclonal
Interleukin 4 Receptor alpha Antagonists
Interleukin-4 Receptor alpha Antagonist

Price Statistics

The NADAC for DUPIXENT 300 MG/2 ML SYRINGE has been published 375 times since Jun 19, 2019, and over the history we have for it it has risen 38.6%. The table below summarizes its recorded NADAC range and movement.

Current price$1011.3804 per ML
All-time high$1011.3804 (Aug 19, 2026)
All-time low$729.5237 (Jun 19, 2019)
52-week high$1011.3804
52-week low$961.8646
Median price$867.3931
Average price$852.1510
Largest weekly change+6.0% (Jan 10, 2024)
Weeks tracked375
Tracking sinceJun 19, 2019

Price History

1W

+0.0%

1M

+0.0%

3M

+0.1%

6M

+0.1%

1Y

+5.1%

3Y

+16.6%

5Y

+31.0%

All

+38.6%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 0%

1 alternative • Same active ingredient

DUPIXENT 300 MG/2 ML PEN
Brand
00024591502•Sanofi-Aventis U.S. LLC
$1009.1638
Save 0%

Related Drugs

Same classification

PRALUENT 75 MG/ML PEN
Brand
61755002002•Regeneron Pharmaceuticals, Inc.
$257.7315
per ML
PRALUENT 150 MG/ML PEN
Brand
61755002102•Regeneron Pharmaceuticals, Inc.
$258.0245
per ML
REPATHA 140 MG/ML SYRINGE
Brand
72511050101•Amgen Inc.
$281.8058
per ML
REPATHA 140 MG/ML SYRINGE
Brand
72511075001•Amgen Inc.
$281.8058
per ML
REPATHA 140 MG/ML SURECLICK
Brand
72511039302•Amgen Inc.
$281.9692
per ML
REPATHA 140 MG/ML SURECLICK
Brand
72511076002•Amgen Inc.
$281.9692
per ML

Frequently asked questions

What is the NADAC price of DUPIXENT 300 MG/2 ML SYRINGE?

The current National Average Drug Acquisition Cost (NADAC) for DUPIXENT 300 MG/2 ML SYRINGE, manufactured by Sanofi-Aventis U.S. LLC, is $1011.3804 per ML (NDC 00024591401), effective Aug 19, 2026.

How has the price of DUPIXENT 300 MG/2 ML SYRINGE changed over time?

Over the history we have for it, the NADAC for DUPIXENT 300 MG/2 ML SYRINGE has risen 38.6%. It has been tracked across 375 weekly CMS publications since Jun 19, 2019.

What are the highest and lowest recorded NADAC prices for DUPIXENT 300 MG/2 ML SYRINGE?

Since Jun 19, 2019, the NADAC for DUPIXENT 300 MG/2 ML SYRINGE has ranged from a low of $729.5237 (Jun 19, 2019) to a high of $1011.3804 (Aug 19, 2026), with a median of $867.3931 per ML.

Are there cheaper alternatives to DUPIXENT 300 MG/2 ML SYRINGE?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DUPIXENT 300 MG/2 ML PEN, is $1009.1638 per ML — about 0% below DUPIXENT 300 MG/2 ML SYRINGE.

Who manufactures DUPIXENT 300 MG/2 ML SYRINGE?

DUPIXENT 300 MG/2 ML SYRINGE (NDC 00024591401) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a brand product.